€1.5M EIT Health / Horizon 2020 Grant
A multi-stakeholder coalition that outlived the grant — 1 of a handful selected from 276 applicants.
The context.
Seasonal influenza is one of Europe's largest annual healthcare burdens — high mortality, system-wide pressure on emergency departments and primary care. Roche Diagnostics EMEA needed to demonstrate the clinical and economic value of its cobas® Liat® point-of-care platform under an EU funding model (EIT Health + Horizon 2020) that rewards real integration — not paperwork coalitions. 276 consortia applied. Only a handful were selected.
What made the difference.
As part of the Roche Diagnostics EMEA Market Access consortium, I supported the grant preparation and shaped the strategic positioning:
Evidence roadmap built into the grant from day one — real-world data (RWD) generation and HTA readiness designed into the proposal, not as a downstream activity
Clinical and market access integrated as one case — not two separate workstreams handed across at submission
Multi-stakeholder coordination — academic anchors, industry partners and patient voices aligned before the proposal was written
Principle.
The grant was the means. HTA readiness and European market adoption were the strategic goals.
Stakeholders aligned.
EIT Health • Horizon 2020 • Roche Diagnostics EMEA Market Access consortium • academic partners • industry • patient organisations • EU policy representatives
Outcome.
Cobas® Liat® was elevated to a clinically validated, cost-effective solution, accelerating market adoption across Europe and reinforcing Roche's leadership in molecular diagnostics.